Thom M, Dubiel M, Kakkar V V, Studd J W
Front Horm Res. 1977;5:192-202. doi: 10.1159/000401994.
The effects of six different regimens of hormone replacement therapy on coagulation, fibrinolysis and platelet aggregation were sudied in 33 symptomatic, post-menopausal women. Studies were performed before and after 3 months of therapy in the six treatment groups, Premarin, Progynova, Harmogen, Serial 28, ethynodiol diacetate and a testosterone and oestradiol implant. No changes in any parameter were detected following administration of Premarin, Progynova or an implant of testosterone and oestradiol. Serial 28 produced a significant increase in plasminogen concentration and increased the extent of platelet aggregation in 0.5 micron adrenalin solution. Harmogen produced an increase in the extent of platelet aggregation in 1.0 micron adrenalin solution, but a decrease in the rate of platelet aggregation in 1.0 micron solution. Ethynodiol diacetate caused a significant decrease in the kaolin-cephalin clotting time but decreased the extent of platelet aggregation in 0.5 and 1.0 micron solutions of adrenalin. FDPs developed following therapy in 9 of the 33 patients. These were evenly distributed between the groups. No patients had any change in anti-Xa concentration, platelet count or platelet aggregation in thrombin.
在33名有症状的绝经后妇女中研究了六种不同激素替代疗法方案对凝血、纤维蛋白溶解和血小板聚集的影响。在六个治疗组（倍美力、诺坤复、哈莫金、28片复方制剂、醋酸炔诺二醇以及睾酮和雌二醇植入剂）中，在治疗前和治疗3个月后进行了研究。服用倍美力、诺坤复或睾酮和雌二醇植入剂后，未检测到任何参数的变化。28片复方制剂使纤溶酶原浓度显著增加，并增加了血小板在0.5微米肾上腺素溶液中的聚集程度。哈莫金使血小板在1.0微米肾上腺素溶液中的聚集程度增加，但使血小板在1.0微米溶液中的聚集速率降低。醋酸炔诺二醇使高岭土-脑磷脂凝血时间显著缩短，但降低了血小板在0.5微米和1.0微米肾上腺素溶液中的聚集程度。33名患者中有9名在治疗后出现纤维蛋白降解产物。这些在各治疗组中分布均匀。没有患者的抗Xa浓度、血小板计数或血小板在凝血酶中的聚集有任何变化。
